Linda M. Henricks

2.6k citations

22 papers · 1.1k indexed · 1 hit paper · h-index 15

Co-authors: Jan H.M. Schellens Jesse J. Swen Jos H. Beijnen Annemieke Cats Ursula Amstutz Kelly E. Caudle Teri E. Klein Howard L. McLeod
Topics: Colorectal Cancer Treatments and Studies (16 papers)Biochemical and Molecular Research (8 papers)Pancreatic and Hepatic Oncology Research (8 papers)
Cited by: Oncology Pharmacology Cancer Research
Journals: Nature Cell Biology British Journal of Cancer Annals of Oncology
Partner nations: Netherlands Switzerland United States

In The Last Decade

Linda M. Henricks

20 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

2017 406 citations Ursula Amstutz, Linda M. Henricks et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Linda M. Henricks

Since Specialization

Citations

This map shows the geographic impact of Linda M. Henricks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda M. Henricks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda M. Henricks more than expected).

Fields of papers citing papers by Linda M. Henricks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda M. Henricks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda M. Henricks. The network helps show where Linda M. Henricks may publish in the future.

Co-authorship network of co-authors of Linda M. Henricks

This figure shows the co-authorship network connecting the top 25 collaborators of Linda M. Henricks. A scholar is included among the top collaborators of Linda M. Henricks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda M. Henricks. Linda M. Henricks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type 2025 ·Fundamental and Clinical Pharmacology ·(unknown),(unknown),Loes E. Visser,Frederiek van den Bos,Linda M. Henricks,(unknown),Femke M. de Man,Hans Gelderblom,Jan H.M. Schellens,Ron H.J. Mathijssen,Henk‐Jan Guchelaar,Johanneke E.A. Portielje,Annemieke Cats,(unknown),Nienke A. de Glas	0
2	Moving average quality control of routine chemistry and hematology parameters – a toolbox for implementation 2022 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Esther van Andel,Linda M. Henricks,(unknown),(unknown),(unknown),(unknown),Huub H. van Rossum,Christa M. Cobbaert,Judith Gillis,Paul W. Schenk,Wendy P. J. den Elzen	9
3	Acute haemolytic transfusion reaction after transfusion of fresh frozen plasma in a neonate—Preventable by using solvent/detergent‐treated pooled plasma? 2022 ·Transfusion Medicine ·Linda M. Henricks,(unknown),Enrico Lopriore,(unknown),Masja de Haas,(unknown),(unknown)	0
4	Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? 2020 ·Clinical Pharmacology & Therapeutics ·(unknown),Hans Gelderblom,Jos H. Beijnen,Annemieke Cats,Henk‐Jan Guchelaar,Linda M. Henricks	47
5	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers 2018 ·European Journal of Cancer ·Carin A.T.C. Lunenburg,Linda M. Henricks,Eva Dreussi,Femke P. Peters,Marta Fiocco,Didier Meulendijks,Giuseppe Toffoli,Henk‐Jan Guchelaar,Jesse J. Swen,Erika Cecchin,Jan H.M. Schellens,Hans Gelderblom	16
6	Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers 2018 ·British Journal of Clinical Pharmacology ·Linda M. Henricks,Bart Jacobs,Didier Meulendijks,Dick Pluim,Daan van den Broek,Niels de Vries,Hilde Rosing,Jos H. Beijnen,Alwin D. R. Huitema,Henk‐Jan Guchelaar,Annemieke Cats,Jan H.M. Schellens	27
7	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants 2018 ·Genes ·Carin A.T.C. Lunenburg,Linda M. Henricks,André B. P. Kuilenburg,Ron H.J. Mathijssen,Jan H.M. Schellens,Hans Gelderblom,Henk‐Jan Guchelaar,Jesse J. Swen	11
8	Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD2A variant: A matched pair analysis 2018 ·International Journal of Cancer* ·Linda M. Henricks,(unknown),Didier Meulendijks,Maarten J. Deenen,Jos H. Beijnen,Anthonius de Boer,Annemieke Cats,Jan H.M. Schellens	39
9	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Updatebreakdown → 2017 ·Clinical Pharmacology & Therapeutics ·Ursula Amstutz,Linda M. Henricks,Steven M. Offer,Julia M. Barbarino,Jan H.M. Schellens,Jesse J. Swen,Teri E. Klein,Howard L. McLeod,Kelly E. Caudle,Robert B. Diasio,Matthias Schwab	406
10	DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update 2017 ·Annals of Oncology ·Linda M. Henricks,Frans L. Opdam,J. H. Beijnen,Annemieke Cats,Jan H.M. Schellens	60
11	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity 2017 ·British Journal of Cancer ·Didier Meulendijks,Linda M. Henricks,Bart Jacobs,(unknown),Maarten J. Deenen,Niels de Vries,Hilde Rosing,Erik van Werkhoven,Anthonius de Boer,Jos H. Beijnen,Caroline M.P.W. Mandigers,Marcel Soesan,Annemieke Cats,Jan H.M. Schellens	81
12	Treatment Algorithm for Homozygous or Compound HeterozygousDPYDVariant Allele Carriers With Low-Dose Capecitabine 2017 ·JCO Precision Oncology ·Linda M. Henricks,(unknown),Femke M. de Man,Astrid A.M. van der Veldt,Paul Hamberg,André B. P. Kuilenburg,Ron H. N. van Schaik,Carin A.T.C. Lunenburg,Henk‐Jan Guchelaar,Jan H.M. Schellens,Ron H.J. Mathijssen	14
13	Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency 2017 ·International Journal of Cancer ·Linda M. Henricks,Ester Siemerink,Hilde Rosing,Judith Meijer,Susan Goorden,Abeltje M. Polstra,Lida Zoetekouw,Annemieke Cats,Jan H.M. Schellens,André B. P. Kuilenburg	23
14	Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines 2016 ·Cancer Chemotherapy and Pharmacology ·Didier Meulendijks,Linda M. Henricks,André B. P. Kuilenburg,Bart Jacobs,(unknown),(unknown),Judith Meijer,Jos H. Beijnen,Hiltje de Graaf,Annemieke Cats,Jan H.M. Schellens	18
15	Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma 2016 ·Journal of Pharmaceutical and Biomedical Analysis ·Bart Jacobs,Hilde Rosing,Niels de Vries,Didier Meulendijks,Linda M. Henricks,Jan H.M. Schellens,Jos H. Beijnen	40
16	Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity 2016 ·International Journal of Cancer ·Didier Meulendijks,Linda M. Henricks,Ursula Amstutz,Tanja K. Froehlich,Carlo R. Largiadèr,Jos H. Beijnen,Anthonius de Boer,Maarten J. Deenen,Annemieke Cats,Jan H.M. Schellens	29
17	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time 2015 ·European Journal of Cancer ·Carin A.T.C. Lunenburg,Linda M. Henricks,Henk‐Jan Guchelaar,Jesse J. Swen,Maarten J. Deenen,Jan H.M. Schellens,Hans Gelderblom	97
18	RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth 2015 ·Nature Cell Biology ·Philippe Depeille,Linda M. Henricks,Robert A. H. van de Ven,Ed Lemmens,Chih‐Yang Wang,Mary Matli,Zena Werb,Kevin M. Haigis,David B. Donner,Robert S. Warren,Jeroen P. Roose	52
19	The use of combinations of monoclonal antibodies in clinical oncology 2015 ·Cancer Treatment Reviews ·Linda M. Henricks,Jan H.M. Schellens,Alwin D. R. Huitema,Jos H. Beijnen	73
20	Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score 2015 ·Pharmacogenomics ·Linda M. Henricks,(unknown),Didier Meulendijks,Hans Gelderblom,Annemieke Cats,Jesse J. Swen,Jan H.M. Schellens,Henk‐Jan Guchelaar	73

About Linda M. Henricks

Linda M. Henricks is a scholar working on Oncology, Geriatrics and Gerontology and Biochemistry, having authored 22 papers that have together received 1.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (16 papers), Biochemical and Molecular Research (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). The work is most often cited by research in Oncology (785 citations), Pharmacology (195 citations) and Cancer Research (112 citations). Linda M. Henricks has collaborated with scholars based in Netherlands, Switzerland and United States. Frequent co-authors include Jan H.M. Schellens, Jesse J. Swen, Jos H. Beijnen, Annemieke Cats, Ursula Amstutz, Kelly E. Caudle, Teri E. Klein, Howard L. McLeod, Henk‐Jan Guchelaar and Robert B. Diasio. Their work appears in journals such as Nature Cell Biology, British Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact